SCHEMBL1075775

SCHEMBL1075775

CN1CCN(Cc2cc3cc(c2)Nc2ncc(Cl)c(n2)Nc2cccc(c2)OCC3)CC1

nearest known ligand 0.56

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 13/20 0.56
JAK1 P23458 13/20 0.56
JAK3 P52333 13/20 0.56
TYK2 P29597 12/20 0.56
ALK Q9UM73 12/20 0.56
STK4 Q13043 1/20 0.40
STK3 Q13188 1/20 0.40
STK26 Q9P289 1/20 0.40
STK24 Q9Y6E0 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL1075186 0.93 JAK2 (0.49) JAK2JAK1JAK3TYK2ALK
SCHEMBL1074519 0.92 JAK2 (0.57) JAK2JAK1JAK3TYK2ALK
SCHEMBL1075749 0.91 JAK2 (0.59) JAK2JAK1JAK3TYK2ALK
SCHEMBL4365864 0.90 JAK2 (0.53) JAK2JAK1JAK3TYK2ALK
SCHEMBL4352979 0.87 JAK2 (0.49) JAK2JAK1JAK3TYK2ALK
Trifluoroacetic Acid SCHEMBL1075181 0.85 JAK2 (0.51) JAK2JAK1JAK3TYK2ALK
Trifluoroacetic Acid SCHEMBL1075892 0.85 JAK2 (0.52) JAK2JAK1JAK3TYK2ALK
SCHEMBL4538506 0.81 JAK2 (0.80) JAK2JAK1JAK3TYK2ALK
SCHEMBL4360615 0.81 JAK2 (0.80) JAK2JAK1JAK3TYK2ALK
SCHEMBL1074494 0.81 ALK (0.55) JAK2JAK1JAK3TYK2ALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US claimed
EP-2274288-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS Incyte Corporation (US) 2011-01-19 EP claimed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US claimed
WO-2009132202-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-10-29 WO claimed
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 US disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 US disclosed
WO-2009132202-A2 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-10-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS JAK2, JAK1, ALK JAK2 1/4885JAK1 2/4885JAK3 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.